Heart Failure

Badimon explains the impact of sotagliflozin’s improvements in left ventricular mass, diastolic function, and 6-minute walk test results in patients without diabetes.

Le discusses the increased risk of mortality and major adverse cardiovascular events in patients with both PAD and AF.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, sat down with Ambarish Pandey, MD, to discuss the revolutionary POLY-HF trial and how polypills can fit into heart failure treatment.

The SGLT2 inhibitor also displayed its efficacy in reducing left ventricular myocardial fibrosis and volume, as well as improving diastolic filling dynamics.

Research presented at the American Heart Association Scientific Sessions 2025 has emphasized the progress which still needs to be made in treating CHD.

Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.

Exposure to nonoptimal temperatures have shown an association with deaths among patients with heart failure.

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.

Risks of myocardial infarction, stroke, heart failure, and other debilitating cardiovascular diseases may be directly influenced by adolescent sugar intake.

Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.

An exploratory analysis of the ATTRibute-CM trial spotlighted acoramidis’s superior efficacy in lowering CVD-related risks versus placebo.

Little discusses 2 recently emerged therapies for TR, spotlighting the benefits and limitations associated with each procedure.

Cedars discusses the difficulties in diagnosing heart failure in this population and how clinicians can provide their patients with better care.

A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.

The Q3 recap for cardiology spotlights major FDA decisions, new heart failure and hypertension guidelines, and top trial results and research.

Read about groundbreaking FDA decisions, exciting new heart failure research, and more.

Recent research refutes the conception that most, if not all, coronary heart disease occurs without typical CVD risk factors.

This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.

Le discusses methods by which clinicians can ease the financial burden of obtaining and adhering to medication for their patients.

The investigative therapy from Windtree Therapeutics also maintained a favorable safety and tolerability profile versus placebo.

Explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.

Recent analyses detail the ongoing risk of hyperkalemia in heart failure patients, highlighting the importance of optimal medication dosing.

An analysis of data from the HELIOS-B trial indicated an overall reduction in GI events among the vutrisiran cohort compared to those receiving placebo.

100% of included participants were successfully defibrillated and exhibited 6-month improvements or stability in the majority of patients.